Primary relevance to vitamin D Vitamin D is a stated subject of this paper.
Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.
Why this paper is included
Supporting source evidence:
In phenotypic analyses (up to n=49 363), increased 25(OH)D concentration was associated with decreased systolic blood pressure (β per 10% increase, −0·12 mm Hg, 95% CI −0·20 to −0·04; p=0·003) and reduced odds of hypertension (odds ratio [OR] 0·98, 95% CI 0·97−0·99; p=0·0003), but not with decreased diastolic blood pressure (β per 10% increase, −0·02 mm Hg, −0·08 to 0·03; p=0·37).
Source: Abstract. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Genetic instrumental-variable study.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Meta-analysis reported · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Association of vitamin D status with arterial blood pressure and hypertension risk: a mendelian randomisation study
Source: Article title.
In the presence of heterogeneity of association between the studies, we used random-effects meta-analyses; otherwise, we tested fixed-effects models.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Association of vitamin D status with arterial blood pressure and hypertension risk: a mendelian randomisation study
Genetic instrumental-variable study · The lancet. Diabetes & endocrinology · 2014
Original publication title
Association of vitamin D status with arterial blood pressure and hypertension risk: a mendelian randomisation study
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Low plasma 25-hydroxyvitamin D (25[OH]D) concentration is associated with high arterial blood pressure and hypertension risk, but whether this association is causal is unknown. We used a mendelian randomisation approach to test whether 25(OH)D concentration is causally associated with blood pressure and hypertension risk.
Source: BackgroundAbstract: What methods does the paper describe?
In this mendelian randomisation study, we generated an allele score (25[OH]D synthesis score) based on variants of genes that affect 25(OH)D synthesis or substrate availability (CYP2R1 and DHCR7), which we used as a proxy for 25(OH)D concentration. We meta-analysed data for up to 108 173 individuals from 35 studies in the D-CarDia collaboration to investigate associations between the allele score and blood pressure measurements. We complemented these analyses with previously published summary statistics from the International Consortium on Blood Pressure (ICBP), the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium, and the Global Blood Pressure Genetics (Global BPGen) consortium.
Source: MethodsAbstract: Findings
In phenotypic analyses (up to n=49 363), increased 25(OH)D concentration was associated with decreased systolic blood pressure (β per 10% increase, −0·12 mm Hg, 95% CI −0·20 to −0·04; p=0·003) and reduced odds of hypertension (odds ratio [OR] 0·98, 95% CI 0·97−0·99; p=0·0003), but not with decreased diastolic blood pressure (β per 10% increase, −0·02 mm Hg, −0·08 to 0·03; p=0·37). In meta-analyses in which we combined data from D-CarDia and the ICBP (n=146 581, after exclusion of overlapping studies), each 25(OH)D-increasing allele of the synthesis score was associated with a change of −0·10 mm Hg in systolic blood pressure (−0·21 to −0·0001; p=0·0498) and a change of −0·08 mm Hg in diastolic blood pressure (−0·15 to −0·02; p=0·01).
When D-CarDia and consortia data for hypertension were meta-analysed together (n=142 255), the synthesis score was associated with a reduced odds of hypertension (OR per allele, 0·98, 0·96−0·99; p=0·001). In instrumental variable analysis, each 10% increase in genetically instrumented 25(OH)D concentration was associated with a change of −0·29 mm Hg in diastolic blood pressure (−0·52 to −0·07; p=0·01), a change of −0·37 mm Hg in systolic blood pressure (−0·73 to 0·003; p=0·052), and an 8·1% decreased odds of hypertension (OR 0·92, 0·87 to 0·97; p=0·002).
Source: FindingsAbstract: Interpretation
Increased plasma concentrations of 25(OH)D might reduce the risk of hypertension. This finding warrants further investigation in an independent, similarly powered study.
Source: InterpretationAuthors’ abstract
Summary
Background
Low plasma 25-hydroxyvitamin D (25[OH]D) concentration is associated with high arterial blood pressure and hypertension risk, but whether this association is causal is unknown. We used a mendelian randomisation approach to test whether 25(OH)D concentration is causally associated with blood pressure and hypertension risk.
Methods
In this mendelian randomisation study, we generated an allele score (25[OH]D synthesis score) based on variants of genes that affect 25(OH)D synthesis or substrate availability (CYP2R1 and DHCR7), which we used as a proxy for 25(OH)D concentration. We meta-analysed data for up to 108 173 individuals from 35 studies in the D-CarDia collaboration to investigate associations between the allele score and blood pressure measurements. We complemented these analyses with previously published summary statistics from the International Consortium on Blood Pressure (ICBP), the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium, and the Global Blood Pressure Genetics (Global BPGen) consortium.
Findings
In phenotypic analyses (up to n=49 363), increased 25(OH)D concentration was associated with decreased systolic blood pressure (β per 10% increase, −0·12 mm Hg, 95% CI −0·20 to −0·04; p=0·003) and reduced odds of hypertension (odds ratio [OR] 0·98, 95% CI 0·97−0·99; p=0·0003), but not with decreased diastolic blood pressure (β per 10% increase, −0·02 mm Hg, −0·08 to 0·03; p=0·37). In meta-analyses in which we combined data from D-CarDia and the ICBP (n=146 581, after exclusion of overlapping studies), each 25(OH)D-increasing allele of the synthesis score was associated with a change of −0·10 mm Hg in systolic blood pressure (−0·21 to −0·0001; p=0·0498) and a change of −0·08 mm Hg in diastolic blood pressure (−0·15 to −0·02; p=0·01).
When D-CarDia and consortia data for hypertension were meta-analysed together (n=142 255), the synthesis score was associated with a reduced odds of hypertension (OR per allele, 0·98, 0·96−0·99; p=0·001). In instrumental variable analysis, each 10% increase in genetically instrumented 25(OH)D concentration was associated with a change of −0·29 mm Hg in diastolic blood pressure (−0·52 to −0·07; p=0·01), a change of −0·37 mm Hg in systolic blood pressure (−0·73 to 0·003; p=0·052), and an 8·1% decreased odds of hypertension (OR 0·92, 0·87 to 0·97; p=0·002).
Interpretation
Increased plasma concentrations of 25(OH)D might reduce the risk of hypertension. This finding warrants further investigation in an independent, similarly powered study.
Publication and source details
Original title: Association of vitamin D status with arterial blood pressure and hypertension risk: a mendelian randomisation study
Karani S Vimaleswaran; Alana Cavadino; Diane J Berry; LifeLines Cohort Study investigators; Rolf Jorde; Aida Karina Dieffenbach; Chen Lu; Alexessander Couto Alves; Hiddo J Lambers Heerspink; Emmi Tikkanen; Joel Eriksson; Andrew Wong; Massimo Mangino; Kathleen A Jablonski; Ilja M Nolte; Denise K Houston; Tarunveer Singh Ahluwalia; Peter J van der Most; Dorota Pasko; Lina Zgaga; Elisabeth Thiering; Veronique Vitart; Ross M Fraser; Jennifer E Huffman; Rudolf A de Boer; Ben Schöttker; Kai-Uwe Saum; Mark I McCarthy; Josée Dupuis; Karl-Heinz Herzig; Sylvain Sebert; Anneli Pouta; Jaana Laitinen; Marcus E Kleber; Gerjan Navis; Mattias Lorentzon; Karen Jameson; Nigel Arden; Jackie A Cooper; Jayshree Acharya; Rebecca Hardy; Olli Raitakari; Samuli Ripatti; Liana K Billings; Jari Lahti; Clive Osmond; Brenda W Penninx; Lars Rejnmark; Kurt K Lohman; Lavinia Paternoster; Ronald P Stolk; Dena G Hernandez; Liisa Byberg; Emil Hagström; Håkan Melhus; Erik Ingelsson; Dan Mellström; Östen Ljunggren; Ioanna Tzoulaki; Stela McLachlan; Evropi Theodoratou; Carla M T Tiesler; Antti Jula; Pau Navarro; Alan F Wright; Ozren Polasek; International Consortium for Blood Pressure (ICBP), Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium, Global Blood Pressure Genetics (Global BPGen) consortium; Caroline Hayward; James F Wilson; Igor Rudan; Veikko Salomaa; Joachim Heinrich; Harry Campbell; Jacqueline F Price; Magnus Karlsson; Lars Lind; Karl Michaëlsson; Stefania Bandinelli; Timothy M Frayling; Catharina A Hartman; Thorkild I A Sørensen; Stephen B Kritchevsky; Bente Lomholt Langdahl; Johan G Eriksson; Jose C Florez; Tim D Spector; Terho Lehtimäki; Diana Kuh; Steve E Humphries; Cyrus Cooper; Claes Ohlsson; Winfried März; Martin H de Borst; Meena Kumari; Mika Kivimaki; Thomas J Wang; Chris Power; Hermann Brenner; Guri Grimnes; Pim van der Harst; Harold Snieder; Aroon D Hingorani; Stefan Pilz; John C Whittaker; Marjo-Riitta Järvelin; Elina Hyppönen
The lancet. Diabetes & endocrinology · 2014
Correspondence to: Prof. Elina Hyppönen, School of Population Health, University of South Australia, GPO Box 2471, Adelaide, SA 5001, Australia elina.hypponen@unisa.edu.auContributed equally
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T21:35:17.088158+00:00
DOI: 10.1016/s2213-8587(14)70113-5 · PMC4582411